A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)

MLA

Macdonald, John S., et al. “A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339).” Investigational New Drugs, vol. 18, no. 2, May 2000, p. 199. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.161072039&authtype=sso&custid=ns315887.

APA

Macdonald, J. S., Jacobson, J. L., Ketchel, S. J., Weiss, G., Taylor, S., Mills, G., Kuebler, J. P., Rivkin, S., & Conrad, M. (2000). A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339). Investigational New Drugs, 18(2), 199.

Chicago

Macdonald, John S., Joth L. Jacobson, Steven J Ketchel, Geoffrey Weiss, Sarah Taylor, Glenn Mills, J. Phillip Kuebler, Saul Rivkin, and Marcel Conrad. 2000. “A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339).” Investigational New Drugs 18 (2): 199. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.161072039&authtype=sso&custid=ns315887.